moclobemide has been researched along with Day Blindness in 1 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Brien, BJ | 1 |
| Novosel, S | 1 |
| Torrance, G | 1 |
| Streiner, D | 1 |
1 trial available for moclobemide and Day Blindness
| Article | Year |
|---|---|
Assessing the economic value of a new antidepressant. A willingness-to-pay approach.
Topics: Adult; Antidepressive Agents; Benzamides; Cost-Benefit Analysis; Depressive Disorder; Female; Humans | 1995 |